论文部分内容阅读
目的研究脑苷肌肽对缺血性脑卒中患者的疗效及血清中胰岛素样生长因子-1(IGF-1)、超敏C反应蛋白(hs CRP)、白细胞介素-18(IL-18)水平的影响。方法选取2013年2月~2015年12月本院收治的缺血性脑卒中患者114例,并随机均分为脑苷肌肽治疗组和常规治疗组,疗程均为21 d,以临床疗效和治疗前、后患者血清中hs CRP、IGF-1、IL-18水平作为观察指标。结果缺血性脑卒中患者经脑苷肌肽治疗后总有效率(91.23%)显著高于常规治疗组(70.18%)(P<0.05);与常规治疗组治疗后比较,脑苷肌肽组患者治疗后血清中IGF-1水平上升,hs CRP、IL-18水平下降(P<0.05)。结论脑苷肌肽对缺血性脑卒中患者疗效显著,作用机制可能与其促进神经营养因子、抑制炎性因子表达有关。
Objective To investigate the therapeutic effect of cerebroside on patients with ischemic stroke and the changes of serum insulin-like growth factor-1 (IGF-1), hsCRP, IL-18 Impact. Methods A total of 114 patients with ischemic stroke admitted to our hospital from February 2013 to December 2015 were randomly divided into two groups. The courses of treatment were 21 days. The clinical efficacy and treatment Serum levels of hs-CRP, IGF-1 and IL-18 in the patients before and after treatment were taken as the observation indexes. Results The total effective rate (91.23%) in patients with ischemic stroke was significantly higher than that in the conventional treatment group (70.18%) (P <0.05). Compared with the conventional treatment group, the patients with cerebroside glycosides treatment Serum IGF-1 levels, hs CRP, IL-18 levels decreased (P <0.05). Conclusion Cerebroside glycosides have a significant effect on patients with ischemic stroke. The mechanism may be related to the promotion of neurotrophic factors and the suppression of the expression of inflammatory cytokines.